Credelio Plus

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

lotilaner, milbemycin oxime

Available from:

Elanco GmbH

ATC code:

QP54AB51

INN (International Name):

lotilaner / milbemycin oxime

Therapeutic group:

Cani

Therapeutic area:

Endectocides

Therapeutic indications:

For use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Authorization status:

autorizzato

Authorization date:

2021-04-14

Patient Information leaflet

                                18
B.
FOGLIETTO ILLUSTRATIVO
19
FOGLIETTO ILLUSTRATIVO:
CREDELIO PLUS 56,25 MG/2,11 MG COMPRESSE MASTICABILI PER CANI
(1,4‒2,8 KG)
CREDELIO PLUS 112,5 MG/4,22 MG COMPRESSE MASTICABILI PER CANI (>
2,8‒5,5 KG)
CREDELIO PLUS 225 MG/8,44 MG COMPRESSE MASTICABILI PER CANI (>
5,5‒11 KG)
CREDELIO PLUS 450 MG/16,88 MG COMPRESSE MASTICABILI PER CANI (>
11‒22 KG)
CREDELIO PLUS 900 MG/33,75 MG COMPRESSE MASTICABILI PER CANI (>
22‒45 KG)
1.
NOME E INDIRIZZO DEL TITOLARE DELL’AUTORIZZAZIONE
ALL’IMMISSIONE IN COMMERCIO E DEL TITOLARE
DELL’AUTORIZZAZIONE ALLA PRODUZIONE RESPONSABILE DEL RILASCIO
DEI LOTTI DI FABBRICAZIONE, SE DIVERSI
Titolare dell’autorizzazione all’immissione in commercio:
Elanco GmbH
Heinz-Lohmann-Str. 4
27472 Cuxhaven
Germania
Produttore responsabile del rilascio dei lotti di fabbricazione:
Elanco France S.A.S
26 Rue de la Chapelle
68330 Huningue
Francia
2.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
Credelio Plus 56,25 mg/2,11 mg compresse masticabili per cani
(1,4‒2,8 kg)
Credelio Plus 112,5 mg/4,22 mg compresse masticabili per cani (>
2,8‒5,5 kg)
Credelio Plus 225 mg/8,44 mg compresse masticabili per cani (>
5,5‒11 kg)
Credelio Plus 450 mg/16,88 mg compresse masticabili per cani (>
11‒22 kg)
Credelio Plus 900 mg/33,75 mg compresse masticabili per cani (>
22‒45 kg)
3.
INDICAZIONE DEL(I) PRINCIPIO(I) ATTIVO(I) E DEGLI ALTRI INGREDIENTI
Ogni compressa masticabile contiene:
CREDELIO PLUS COMPRESSE
MASTICABILI
LOTILANER (MG)
MILBEMICINA OSSIMA (MG)
Cani (1,4‒2,8 kg)
56,25
2,11
Cani (> 2,8‒5,5 kg)
112,5
4,22
Cani (> 5,5‒11 kg)
225
8,44
Cani (> 11‒22 kg)
450
16,88
Cani (> 22‒45 kg)
900
33,75
Compressa masticabile rotonda biconvessa di colore dal bianco al beige
con macchie brunastre.
4.
INDICAZIONE(I)
Per l’uso in cani con o a rischio di infestazioni/infezioni miste da
zecche, pulci, nematodi
gastrointestinali, dirofilaria cardiopolmonare e/o strongili
polmonari. Questo medicinale veterinario è
indicato per l’uso quando è richiesto contemporaneamente un
trattamento cont
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ALLEGATO I
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
2
1.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
Credelio Plus 56,25 mg/2,11 mg compresse masticabili per cani
(1,4‒2,8 kg)
Credelio Plus 112,5 mg/4,22 mg compresse masticabili per cani (>
2,8‒5,5 kg)
Credelio Plus 225 mg/8,44 mg compresse masticabili per cani (>
5,5‒11 kg)
Credelio Plus 450 mg/16,88 mg compresse masticabili per cani (>
11‒22 kg)
Credelio Plus 900 mg/33,75 mg compresse masticabili per cani (>
22‒45 kg)
2.
COMPOSIZIONE QUALITATIVA E QUANTITATIVA
PRINCIPI ATTIVI:
Ogni compressa masticabile contiene:
Per l’elenco completo degli eccipienti, vedere paragrafo 6.1.
3.
FORMA FARMACEUTICA
Compressa masticabile.
Compressa masticabile rotonda biconvessa di colore dal bianco al beige
con macchie brunastre e bordi
smussati, con la lettera “I” incisa su un lato della compressa.
4.
INFORMAZIONI CLINICHE
4.1
SPECIE DI DESTINAZIONE
Cani
4.2
INDICAZIONI PER L’UTILIZZAZIONE, SPECIFICANDO LE SPECIE DI
DESTINAZIONE
Per l’uso in cani con, o a rischio di, infestazioni/infezioni miste
da zecche, pulci, nematodi
gastrointestinali, dirofilaria cardiopolmonare e/o strongili
polmonari.
Questo medicinale veterinario è indicato per l’uso quando è
richiesto contemporaneamente un
trattamento contro zecche/pulci e nematodi gastrointestinali o un
trattamento contro zecche/pulci e la
prevenzione della filariosi cardiopolmonare/angiostrongilosi.
Zecche e pulci
Per il trattamento delle infestazioni da zecche (
_Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus _
_sanguineus _
e
_ I. hexagonus_
) e da pulci (
_Ctenocephalides felis _
e
_C. canis_
) nei cani.
Questo medicinale veterinario fornisce immediata e persistente
attività zecchicida e pulcicida
per 1 mese.
Il medicinale veterinario può essere utilizzato come parte di una
strategia di trattamento per il
controllo della dermatite allergica da pulci (DAP).
CREDELIO PLUS COMPRESSE
LOTILANER
MILBEMICINA OSSIMA
Cani (1,4‒2,8 kg)
56,25 mg
2,11 mg
Cani (> 2,8‒5,5 kg)
112,5 mg
4,22 mg
Cani (> 5,5
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-08-2021
Public Assessment Report Public Assessment Report Bulgarian 04-08-2021
Patient Information leaflet Patient Information leaflet Spanish 04-08-2021
Public Assessment Report Public Assessment Report Spanish 04-08-2021
Patient Information leaflet Patient Information leaflet Czech 04-08-2021
Public Assessment Report Public Assessment Report Czech 04-08-2021
Patient Information leaflet Patient Information leaflet Danish 04-08-2021
Public Assessment Report Public Assessment Report Danish 04-08-2021
Patient Information leaflet Patient Information leaflet German 04-08-2021
Public Assessment Report Public Assessment Report German 04-08-2021
Patient Information leaflet Patient Information leaflet Estonian 04-08-2021
Public Assessment Report Public Assessment Report Estonian 04-08-2021
Patient Information leaflet Patient Information leaflet Greek 04-08-2021
Public Assessment Report Public Assessment Report Greek 04-08-2021
Patient Information leaflet Patient Information leaflet English 04-08-2021
Public Assessment Report Public Assessment Report English 04-08-2021
Patient Information leaflet Patient Information leaflet French 04-08-2021
Public Assessment Report Public Assessment Report French 04-08-2021
Patient Information leaflet Patient Information leaflet Latvian 04-08-2021
Public Assessment Report Public Assessment Report Latvian 04-08-2021
Patient Information leaflet Patient Information leaflet Lithuanian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-08-2021
Public Assessment Report Public Assessment Report Lithuanian 04-08-2021
Patient Information leaflet Patient Information leaflet Hungarian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 04-08-2021
Public Assessment Report Public Assessment Report Hungarian 04-08-2021
Patient Information leaflet Patient Information leaflet Maltese 04-08-2021
Public Assessment Report Public Assessment Report Maltese 04-08-2021
Patient Information leaflet Patient Information leaflet Dutch 04-08-2021
Public Assessment Report Public Assessment Report Dutch 04-08-2021
Patient Information leaflet Patient Information leaflet Polish 04-08-2021
Public Assessment Report Public Assessment Report Polish 04-08-2021
Patient Information leaflet Patient Information leaflet Portuguese 04-08-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 04-08-2021
Public Assessment Report Public Assessment Report Portuguese 04-08-2021
Patient Information leaflet Patient Information leaflet Romanian 04-08-2021
Public Assessment Report Public Assessment Report Romanian 04-08-2021
Patient Information leaflet Patient Information leaflet Slovak 04-08-2021
Public Assessment Report Public Assessment Report Slovak 04-08-2021
Patient Information leaflet Patient Information leaflet Slovenian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 04-08-2021
Public Assessment Report Public Assessment Report Slovenian 04-08-2021
Patient Information leaflet Patient Information leaflet Finnish 04-08-2021
Public Assessment Report Public Assessment Report Finnish 04-08-2021
Patient Information leaflet Patient Information leaflet Swedish 04-08-2021
Public Assessment Report Public Assessment Report Swedish 04-08-2021
Patient Information leaflet Patient Information leaflet Norwegian 04-08-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 04-08-2021
Patient Information leaflet Patient Information leaflet Icelandic 04-08-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 04-08-2021
Patient Information leaflet Patient Information leaflet Croatian 04-08-2021
Public Assessment Report Public Assessment Report Croatian 04-08-2021

Search alerts related to this product

View documents history